Press Releases

Date Title and Summary Additional Formats
Toggle Summary Radius Exceeds 2018 Financial Guidance and Provides Business Update at the 37th Annual J.P. Morgan Healthcare Conference
WALTHAM, Mass. , Jan. 07, 2019 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq: RDUS), today announced that it has exceeded its 2018 financial guidance with full-year TYMLOS® U.S. net sales surpassing the upper range of $95 to $98 million . Radius closed 2018 with a $235 million cash, cash
View HTML
Toggle Summary Radius Exceeds 2019 Financial Guidance and Provides Business Update at the 38th Annual J.P. Morgan Healthcare Conference
Full-Year 2019 TYMLOS U.S. net revenue exceeds financial guidance, surpassing $172M . TYMLOS exits 2019 with 52% market share in new patients 1 , on track for market leadership in 2020. Radius delivers strong year-end balance sheet with $160M cash 2 balance and expects to achieve profitability
View HTML
Toggle Summary Radius Health & Menarini Group Provide Elacestrant Update
Target enrollment milestone reached in the Phase 3 EMERALD study Life cycle planning advancing in parallel with current Phase 3 monotherapy program WALTHAM, Mass. and FLORENCE, Italy , Sept. 24, 2020 (GLOBE NEWSWIRE) -- Radius Health , Inc. (“Radius” or the “Company”) (Nasdaq: RDUS) and the
View HTML
Toggle Summary Radius Health Announced That it Has Appointed Catherine Friedman to the Board of Directors
WALTHAM, Mass., Aug. 18, 2015 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), a science-driven biopharmaceutical company developing new therapeutics for patients with advanced osteoporosis as well as other serious endocrine-mediated diseases including hormone responsive metastatic breast
View HTML
Toggle Summary Radius Health Announced That it Has Appointed Debasish Roychowdhury, MD, to Its Board of Directors and the Formation of the Radius Oncology Clinical Advisory Board (OCAB)
WALTHAM, Mass., July 20, 2015 (GLOBE NEWSWIRE) -- Radius Health, Inc. (NASDAQ:RDUS) (the "Company"), a science-driven biopharmaceutical company developing new therapeutics for patients with advanced osteoporosis as well as other serious endocrine-mediated diseases including hormone responsive
View HTML
Toggle Summary Radius Health Announced Today That it Has Acquired the License to Develop and Market RAD1901 in Japan, and Has Hired Dinesh Purandare, Former Sanofi Oncology Executive to the Position of Senior Vice President (SVP) and Head of Global Oncology at Radius
WALTHAM, Mass., March 9, 2015 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), a science-driven biopharmaceutical company developing new therapeutics for patients with advanced osteoporosis as well as other serious endocrine-mediated diseases including hormone responsive cancers, today
View HTML
Toggle Summary Radius Health Announces CEO Leadership Transition
Jesper Hoeiland to step down as President and Chief Executive Officer in order to return to Denmark with his family Jesper will serve as a Senior Advisor to the Company to help facilitate a smooth transition Kelly Martin has been appointed President and Chief Executive Officer WALTHAM, Mass.
View HTML
Toggle Summary Radius Health Announces Change to its Board of Directors
BOSTON , Jan. 04, 2021 (GLOBE NEWSWIRE) -- Radius Health , Inc. (“Radius” or the “Company”) (Nasdaq: RDUS) announced today that Machelle Sanders and Dr. Andrew C. von Eschenbach have joined the Company’s board of directors. Ms. Sanders and Dr. von Eschenbach will fill vacancies created by the
View HTML
Toggle Summary Radius Health Announces Clinical Collaboration With a Leading Pharmaceutical Company to Evaluate RAD1901 Combination Regimens in Advanced Breast Cancer
- Collaboration will evaluate Radius' investigational drug, RAD1901, in combination with Novartis investigational CDK4/6 inhibitor LEE011 for the treatment of breast cancer -Additional studies are planned to evaluate effects of combining RAD1901 with BYL719, Novartis investigational PI3K inhibitor
View HTML
Toggle Summary Radius Health Announces Commercial Agreement with Paladin Labs for Abaloparatide in Canada
Agreement incorporates TYMLOS ® and abaloparatide-TD Consideration includes upfront payment, milestones based on clinical, regulatory and commercial progression, as well as royalties Key first step in expanding the global footprint for the abaloparatide asset beyond the U.S.
View HTML